Compare Stocks: CHRS, AMPH, ABUS, and TBPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.34 -1.6%	$4.53	$3.26 ▼ $5.38	$871.14M	0.62	1.91 million shs	1.17 million shs
AMPH Amphastar Pharmaceuticals	$19.94 -2.2%	$19.54	$16.65 ▼ $31.26	$898.61M	0.89	385,438 shs	367,623 shs
CHRS Coherus Oncology	$1.41 -4.1%	$1.48	$0.81 ▼ $2.62	$226.75M	0.97	676,129 shs	436,922 shs
TBPH Theravance Biopharma	$16.86 +0.1%	$16.71	$10.82 ▼ $21.03	$868.67M	0.17	580,184 shs	369,696 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.59%	-0.91%	-8.25%	+0.46%	+31.52%
AMPH Amphastar Pharmaceuticals	-2.16%	+6.52%	-0.80%	-8.87%	-6.56%
CHRS Coherus Oncology	-4.08%	0.00%	-2.08%	-21.67%	+45.36%
TBPH Theravance Biopharma	+0.06%	0.00%	-0.71%	+0.42%	+52.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.34 -1.6%	$4.53	$3.26 ▼ $5.38	$871.14M	0.62	1.91 million shs	1.17 million shs
AMPH Amphastar Pharmaceuticals	$19.94 -2.2%	$19.54	$16.65 ▼ $31.26	$898.61M	0.89	385,438 shs	367,623 shs
CHRS Coherus Oncology	$1.41 -4.1%	$1.48	$0.81 ▼ $2.62	$226.75M	0.97	676,129 shs	436,922 shs
TBPH Theravance Biopharma	$16.86 +0.1%	$16.71	$10.82 ▼ $21.03	$868.67M	0.17	580,184 shs	369,696 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.59%	-0.91%	-8.25%	+0.46%	+31.52%
AMPH Amphastar Pharmaceuticals	-2.16%	+6.52%	-0.80%	-8.87%	-6.56%
CHRS Coherus Oncology	-4.08%	0.00%	-2.08%	-21.67%	+45.36%
TBPH Theravance Biopharma	+0.06%	0.00%	-0.71%	+0.42%	+52.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.00	Hold	$5.00	15.21% Upside
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.00	10.33% Upside
CHRS Coherus Oncology	2.75	Moderate Buy	$8.67	514.66% Upside
TBPH Theravance Biopharma	2.00	Hold	$19.40	15.07% Upside

Current Analyst Ratings Breakdown

Latest CHRS, AMPH, ABUS, and TBPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2026	AMPH Amphastar Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	AMPH Amphastar Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/7/2026	TBPH Theravance Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$15.00 ➝ $17.00
6/29/2026	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/29/2026	AMPH Amphastar Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform	$25.00 ➝ $20.00
6/29/2026	TBPH Theravance Biopharma	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/22/2026	AMPH Amphastar Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/8/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$23.00 ➝ $20.00
5/27/2026	TBPH Theravance Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$14.08M	60.89	N/A	N/A	$0.40 per share	10.85
AMPH Amphastar Pharmaceuticals	$719.89M	1.22	$4.16 per share	4.79	$17.17 per share	1.16
CHRS Coherus Oncology	$46.88M	4.64	N/A	N/A	$0.50 per share	2.82
TBPH Theravance Biopharma	$107.46M	8.09	N/A	N/A	$5.86 per share	2.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.83	5.23	N/A	N/A	83.95%	129.32%	112.24%	8/5/2026 (Estimated)
AMPH Amphastar Pharmaceuticals	$98.09M	$1.66	12.01	7.15	4.30	11.00%	15.12%	7.14%	8/6/2026 (Estimated)
CHRS Coherus Oncology	$168.02M	$1.67	0.84	N/A	N/A	397.30%	-198.90%	-46.65%	8/5/2026 (Estimated)
TBPH Theravance Biopharma	$105.89M	$2.20	7.66	62.44	N/A	104.34%	18.84%	10.94%	8/11/2026 (Estimated)

Latest CHRS, AMPH, ABUS, and TBPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	N/A	N/A	N/A	$22.49 million	N/A
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.66	N/A	N/A	N/A	$179.92 million	N/A
8/5/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	N/A	N/A	N/A	$0.70 million	N/A
8/5/2026	Q2 2026	CHRS Coherus Oncology	-$0.1150	N/A	N/A	N/A	$14.41 million	N/A
5/13/2026	Q1 2026	ABUS Arbutus Biopharma	-$0.03	$0.87	+$0.90	$0.87	$0.75 million	$179.13 million
5/11/2026	Q1 2026	CHRS Coherus Oncology	-$0.2633	-$0.25	+$0.0133	-$0.28	$14.22 million	$12.31 million
5/7/2026	Q1 2026	AMPH Amphastar Pharmaceuticals	$0.70	$0.42	-$0.28	$0.14	$173.46 million	$171.17 million
5/7/2026	Q1 2026	TBPH Theravance Biopharma	$0.0280	-$0.10	-$0.1280	-$0.10	$17.78 million	$17.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	54.26	54.26
AMPH Amphastar Pharmaceuticals	0.79	3.85	2.82
CHRS Coherus Oncology	0.47	1.56	1.52
TBPH Theravance Biopharma	N/A	13.14	13.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
AMPH Amphastar Pharmaceuticals	65.09%
CHRS Coherus Oncology	72.82%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
AMPH Amphastar Pharmaceuticals	29.60%
CHRS Coherus Oncology	8.08%
TBPH Theravance Biopharma	7.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	197.54 million	158.23 million	Optionable
AMPH Amphastar Pharmaceuticals	1,976	44.09 million	31.04 million	Optionable
CHRS Coherus Oncology	330	154.25 million	141.79 million	Optionable
TBPH Theravance Biopharma	110	51.55 million	47.61 million	Optionable

CHRS, AMPH, ABUS, and TBPH Headlines

Recent News About These Companies

Swiss National Bank Invests $1.22 Million in Theravance Biopharma, Inc. $TBPH

39 minutes ago | marketbeat.com

103,000 Shares in Theravance Biopharma, Inc. $TBPH Purchased by Rangeley Capital LLC

July 27, 2026 | marketbeat.com

Precision Wealth Strategies LLC Takes $1.02 Million Position in Theravance Biopharma, Inc. $TBPH

July 19, 2026 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - Here's Why

July 17, 2026 | marketbeat.com

Theravance Biopharma Stock Dividends | NASDAQ:TBPH | Benzinga

July 13, 2026 | benzinga.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Hold" by Analysts

July 9, 2026 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells $428,712.51 in Stock

July 2, 2026 | insidertrades.com

Theravance Stock Down 3% After Zymeworks Announces Buyout

June 30, 2026 | zacks.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)

June 29, 2026 | prnewswire.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

June 29, 2026 | businesswire.com

Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders

June 29, 2026 | prnewswire.com

Theravance Biopharma, Inc.: Theravance Biopharma Enters Into Definitive Agreement To Be Acquired By Zymeworks For $17.00 Per Share In Cash Plus A Contingent Value Right

June 29, 2026 | finanznachrichten.de

Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders

June 29, 2026 | finance.yahoo.com

Zymeworks strikes $929 million deal for Theravance Biopharma

June 29, 2026 | reuters.com

Zymeworks to Acquire Theravance Biopharma, Inc.

June 29, 2026 | financialpost.comF

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

June 29, 2026 | prnewswire.com

Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares of Stock

June 18, 2026 | insidertrades.com

TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle

May 8, 2026 | zacks.com

Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock

May 7, 2026 | zacks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH

May 7, 2026 | prnewswire.com

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, AMPH, ABUS, and TBPH Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$4.34 -0.07 (-1.59%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.32 -0.01 (-0.35%)

As of 07/31/2026 07:34 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Amphastar Pharmaceuticals NASDAQ:AMPH

$19.94 -0.44 (-2.16%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$19.90 -0.04 (-0.18%)

As of 07/31/2026 07:46 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Coherus Oncology NASDAQ:CHRS

$1.41 -0.06 (-4.08%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.42 +0.01 (+0.35%)

As of 07/31/2026 07:34 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Theravance Biopharma NASDAQ:TBPH

$16.86 +0.01 (+0.06%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$16.86 +0.00 (+0.03%)

As of 07/31/2026 05:21 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, AMPH, ABUS, and TBPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, AMPH, ABUS, and TBPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, AMPH, ABUS, and TBPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, AMPH, ABUS, and TBPH Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Amphastar Pharmaceuticals NASDAQ:AMPH

Coherus Oncology NASDAQ:CHRS

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, AMPH, ABUS, and TBPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, AMPH, ABUS, and TBPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, AMPH, ABUS, and TBPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, AMPH, ABUS, and TBPH Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Amphastar Pharmaceuticals NASDAQ:AMPH

Coherus Oncology NASDAQ:CHRS

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools